GlassScriptPhysician profile
Katherine Hays
NPI 1063432821
$5,194.57
in general payments reported to CMS, 2019-2025
34 companies · $1,070 in 2025
The $1,070 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $696 · 2020: $643 · 2021: $844 · 2022: $722 · 2023: $681 · 2024: $539 · 2025: $1,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $610.57 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $422.04 | 2019-2025 | |
| Abbott Laboratories | $404.10 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $370.52 | 2019-2024 | Farxiga, Wainua |
| Pfizer INC. | $357.36 | 2019-2025 | |
| Medtronic, INC. | $333.81 | 2022-2025 | Aurora Ev-Icd Mri Surescan, Linq II |
| Novo Nordisk INC | $277.27 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $256.89 | 2019-2023 | Opsumit |
| Amgen INC. | $256.46 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $222.82 | 2019-2025 | (Ck4) Mcot, Extended Holter, Ecc Solutions |
| Teleflex LLC | $206.86 | 2025 | Manta |
| Merck Sharp & Dohme LLC | $203.68 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Sanofi-Aventis U.S. LLC | $161.56 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.31 | 2020-2025 | Lifevest |
| Kci USA, INC. | $124.75 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $123.86 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.90 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $94.08 | 2021-2024 | Camzyos, Eliquis |
| Amarin Pharma, INC. | $93.08 | 2019-2021 | |
| Braemar Manufacturing, LLC | $71.42 | 2019 | |
| Kestra Medical Technology Services, INC. | $63.97 | 2024 | Assure Wcd |
| Ethicon US, LLC | $38.51 | 2024 | Stratafix |
| Glaxosmithkline, LLC. | $31.78 | 2025 | Shingrix |
| Irhythm Technologies, INC. | $29.83 | 2019-2022 | |
| Terumo Medical Corporation | $29.41 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $27.62 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $26.73 | 2019 | |
| Lundbeck LLC | $21.44 | 2019 | |
| Chiesi USA, INC. | $17.96 | 2019 | |
| Stryker Corporation | $17.81 | 2025 | Triever20 |
| Lilly USA, LLC | $17.24 | 2025 | Zepbound, Mounjaro |
| Edwards Lifesciences Corporation | $15.56 | 2019 | |
| Boston Scientific Corporation | $14.55 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Hays listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.